STAT

The creator of the pig-human chimera keeps proving other scientists wrong

The Salk Institute's Juan Carlos Izpisua Belmonte fiddles with genes and embryos to answer fundamental questions of biology and grow human organs in pigs.

LA JOLLA, Calif. — It was the salamanders.

Juan Carlos Izpisua Belmonte had spent years probing the inner workings of embryos, ferreting out the genes that give a body its shape or allow wings to form instead of legs. He’d tracked wafting chemical messengers that, like traffic police, guide streams of dividing cells either left or right. He’d even found a way to tweak animals to grow extra limbs. But one thing he never stopped thinking about was how salamanders could lose parts of their bodies and then regrow perfect replacements. Was it possible, he wondered, that humans might do the same?

The dogged pursuit of that question has pushed Izpisua Belmonte to the forefront of biology as he’s made one stunning discovery after another — many before the world is ready to deal with their far-reaching ethical implications.

Early this year, seeking a way to grow human organs for transplant, his group announced it had created pig-human chimeras — fetal pigs with human cells mixed in. His Salk Institute lab has discovered two new kinds of stem cells, including one considered the pinnacle of stem cells because, in addition to being able to create every type of cell in the body, it can also form tissues like the placenta and amniotic sac that embryos need to survive. Last December, they used a technique in mice that may help reverse aging by reprogramming adult cells back to their youth.

Read more: First human-pig chimeras created, sparking hopes for transplantable organs — and debate

His lab also played a supporting role in two extremely controversial studies conducted at Oregon Health and Science University: the work reported last week on the editing of, as well as the creation last year of in an effort to eliminate the mutations that lead to mitochondrial disease.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks